Recently, the potential use of cellular and circulating miRNAs as biomarkers for AML diagnosis/prognosis, and as therapeutic targets has been widely explored, and many miRNAs were found to be associated with HDAC2 dysfunction in leukemia 13. This evidence concerns the gene HDAC2 and acute myeloid leukemia.